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Abstract
Background: Uterine myomas co-existing with pregnancy could cause obstetric complications.
Objectives: To assess sonographically the frequency of  occurrence and effect of  uterine myomas co-existing with pregnancy.
Methods:  A longitudinal study was conducted during a period of 23 months. A convenience sample of 816 consecutive
consenting pregnant women who met the inclusion criteria was evaluated during routine prenatal ultrasound scan. The
women were referred for prenatal sonography. One hundred of  the subjects who had myoma co-existing with pregnancy
and another 100 subjects without myoma were selected for follow-up. These groups were followed up till delivery and
obstetric complications and outcomes were documented. Any changes in size and growth rate of myoma were documented.
Results:  Subjects with myoma co-existing with pregnancy were 12.3%. This was commoner with increasing maternal age.
An increase was observed in myoma mean size from 60mm to 63mm from the 1st scan sequence to the 2nd scan sequence and
a reduction from 63mm to 59mm in the 3rd scan sequence. Myoma growth rate was 0.667mm per week. Myomas in
pregnancy especially large ones caused more complications during delivery when compared to pregnancies without myomas.
Conclusion: Routine sonography is important in pregnancy management of  uterine myomas co-existing with pregnancy.
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Uterine leiomyoma, also known as uterine fibroid is
a mass of compacted smooth muscle and fibrous
tissue diagnosed in about 20% to 25% of women
older than 25 years.1 Aetiologies of  uterine
leiomyomas are unknown but several predisposing
factors have been identified including age (late
reproductive years), African-American ethnicity,
nulliparity, obesity and genetics.2 It is seven times
commoner in blacks compared to Caucasians3 and
can grow so large to cause negative impact on
obstetric outcome if  co-existing with pregnancy.
Estrogen is recognized as promoter of tumour
growth. During pregnancy, the influx of  this
hormone is said to have effects on the co-existing
myomas. Uterine myomas usually develop before
pregnancy and are usually discovered during
ultrasound examination particularly in patients who
present with symptoms.
There are five common types of uterine
fibroids. They are identified by where they are located
in the uterus. Subserosal fibroids develop in the outer
portion of the uterus and grow outward. These
fibroids can be painful if they are large and press on
the other organs. They usually do not affect a
woman’s menstrual flow. Submucous fibroids
develop just under the lining of  the uterine cavity.
These are the least common types of fibroid. They
often cause very heavy, long menstrual periods.
Pendunculated uterine fibroid occurs when the
fibroid grows on a stalk. These can grow in the
uterine cavity or on the outside of  the uterus.
Intramural fibroid develops and localizes within the
myometrium. During pregnancy, retro-placental
fibroid can be seen behind the placenta where they
may exert pressure on it.
Uterine fibroids also have implications in
non-pregnant women of reproductive age. About
1 in every 15 women with infertility has fibroids,
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but the fibroids are usually innocent bystanders.4 They
cause only 2% to 3% of  cases of  infertility. Fibroids
that block one or both of the fallopian tubes may
prevent sperm from fertilizing an egg while fibroids
that fill the uterine cavity may block implantation of
a newly fertilized egg.5
Based on risk factors for myoma development which
include diet, race, geographical and socio-economic
differences6 - 9, our locality has a greater susceptibility
of rapid myoma growth. Therefore, it is being
advocated that routine ultrasound investigation
should be encouraged in all pregnancies in order to
detect myomas or any other lesions early enough
for better obstetric management.10
Ultrasound and magnetic resonance imaging
(MRI) are modalities of choice for diagnosis of
uterine fibroids.11 Location, size, number and extent
of myoma penetration into the myometrium are
usually evaluated by MRI without the use of
gadolinium contrast. The drawbacks of MRI in
evaluation of uterine fibroids include high cost and
low accessibility compared to ultrasound which is
simple, non- invasive, affordable and more readily
available. X-radiation based modalities are rarely used
in pregnancy due to radiation hazards to the fetus.
This study is aimed at assessing uterine
leiomyomas co-existing with pregnancy and
associated obstetric complications by routine prenatal
sonography.
Methods
This was a longitudinal study conducted during a
period of  23 months.  The study was carried out at
departments of  Radiology, and Obstetrics and
Gynaecology, Federal Medical Centre, Owerri,
Nigeria from August, 2009 to July, 2011. Ethical
approval was obtained from the Research Ethics
Committee of the hospital before commencement
of  the study. A convenience sample of  816
consecutive consenting pregnant women who met
the inclusion criteria was evaluated during routine
prenatal ultrasound scan. The women were attending
antenatal clinic in the hospital and were referred to
have prenatal sonography. Informed consent was
obtained from subjects who met the inclusion criteria
before being enlisted in the study. One hundred of
the subjects who had myoma co-existing with
pregnancy and another 100 subjects without myoma
(control group) were selected for follow-up. The
two groups were followed up till delivery and
obstetric complications and outcomes were
documented appropriately. Inclusion criterion was
singleton pregnancy of between 6 weeks and 40
weeks gestational age. Exclusion criteria were non
gravid women with myoma, ectopic pregnancy and
multiple pregnancies. Multiple pregnancies are known
to be high-risk pregnancies with a number of
complications developing which may not be
necessarily associated with co-existing myoma.
Subjects in whom myomas were identified
were rescanned thrice at 3 – 6 weeks (4.5 weeks
mean interval) before delivery to document any
changes in size and growth velocity of myoma.
Ultrasound Equipment: The subjects were examined
with S1-400, SS1- 600 (Siemens AG, Germany), and
GE 8900 (General Electric Company, USA) real
time ultrasound machines with 3.5MHz, 5.0HMz and
7.5MHz curvilinear and linear transducers
respectively. The choice of  these probes was based
on varying degrees of  penetration needed. Validity
and reliability of the equipment were tested prior to
the study through pilot study and quality assurance.
The entire abdomino-pelvic area was scanned in both
longitudinal and transverse planes using transducer
manipulations4 to assess fetal viability, presentation,
gestational age (GA), expected date of delivery
(EDD), and presence, location and size of co-existing
myoma. Myomas were measured in three dimensions
in millimetre (height, width and length) to determine
the mean size. Also location/type of myoma was
determined in each subject and documented.
Demographic and clinical details of the
subjects as written in the ultrasound request forms
were extracted for use in the study. These include
patient age, routine scan, unsure date (in the initial
scan), and clinical impressions such as mal-
presentation, premature rupture of membrane
(PROM), severe pelvic pain, bleeding, missed
abortion/intrauterine death (IUD), intrauterine
growth restriction (IUGR) (in subsequent scans).
Statistical analysis
Data collected were analysed using the Statistical
Package for Social Sciences (SPSS) version 19.0
(Chicago, Illinois, USA). Both descriptive and
inferential statistics were carried out. For the purpose
of inference, statistical significance was considered
at p < 0.05. Incidence of myoma co-existing with
pregnancy was expressed as percentage of total
number of subjects evaluated. Growth velocity was
calculated using simple descriptive statistics.
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Results
Table 1 shows the age distribution of  subjects and
distribution of fibroid among the subjects according
to age. The mean age of the subjects with myoma
was calculated from the raw data to be 31.6 ± 4.5
Table 1: Age distribution of  subjects and distribution of  fibroid among the subjects according to
age
years while the mean age for subjects without myoma
was 29.1 ± 5.5 years. An occurrence of  12.3% for
myoma co-existing with pregnancy was found. The
occurrence of fibroid was significantly more in older
subjects; 25 – 39 years (p < 0.05).
Note: The mean age of the subjects with myoma was calculated to be 31.6 ± 4.5 years while the mean age of the group
without myoma was 29.1 ± 5.5 years. These were calculated from the raw data.
Figure 1 shows that pedunculated subserous and
retroplacental myomas had the lowest occurrences
compared to other types of myoma. Majority of
the myomas co-existing with pregnancy were
multiple (51.0%, n = 51) while single myomas


















Figure 1: Types of  fibroid observed in pregnant women studied
Table 2 reveals that there was an increase in aggregate
myoma mean size of 60mm to 63mm between the
first scan and the second scan. A 3 to 6 weeks interval
of scan (mean = 4.5 weeks) was allowed. The
growth rate was calculated to be 0.667mm per week.
Table 3 shows that there was weak but statistically
significant relationship between the mean size of
myoma and GA (p = 0.01).  No significant
relationship was observed between myoma mean
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Total 100  (12.3%) 716    (87.7%) 816 (100.0%)   
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Median Minimum Maximum SD >75 <25 25 to 75
Mean size of 1st scan (mm) 60 55.8 10 140 28 28.3% 8.0% 63.8%
Mean size of 2nd scan (mm) 63 58.1 15 159 29 31.2% 5.8% 63.0%
Mean size of 3rd scan (mm) 59 51.0 9 139 29 27.2% 4.9% 67.9%
Table 3: Correlation of  mean size of  fibroid, gestational age and maternal age
Mean size of 
fibroid
Gestational age (weeks) Pearson’s correlation Coefficient 0.111*
0.037p-value
Maternal  age 
(years)
Pearson’s correlation Coefficient 0.035
0.515p-value
       * Correlation is significant at the 0.05 level (2-tailed)
Table 4 shows that a significant majority of  patients
with myoma co-existing with pregnancy (65%, n =
65) had complications during the course of
pregnancy while 35% (n = 35) had no complications
(p < 0.05). The occurrence of obstetric
complications such as abortion or fetal death was
observed in all the age group except women between
the age groups of  15-19 years and 20-24 years. The
15-19 years age group had no complications at all.
The least complication observed was premature
rupture of membrane (PROM) which accounted
for only 2% (n = 2). Subjects without myoma who
were followed up also had obstetric complications
seen in all the age groups as shown in table 5. Twenty
one subjects (21%) without myoma co-existing with
pregnancy had complications while 79% of the
subjects (n = 79) had no complications. The
commonest complication noted in both groups was
pelvic pains as shown in tables 4 and 5 while the
least complication was PROM.





































































Total 33 (33%) 5 (5%) 2 (2%) 15(15%) 4 (4%) 5(5%) 35(35%) 100 
(100%)
Figure 2 shows that some patients with myoma size
of  21mm or bigger had Caesarean Section (CS)
before the onset of labour, with the proportion
increasing with increasing size of myoma. Patients
with myoma size of 1-20 mm had spontaneous
vaginal delivery (SVD).
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Figure 2: Co-existing myoma size and mode of  delivery






































































Total 3 (3%) 3 (3%) 2 (2%) 7 (7%) 3 (3%) 3 (3%) 79 (79%) 100 (100%)
Discussion
The present study shows an incidence of 12.3%
myoma co-existing with pregnancy. Myoma co-
existing with pregnancy was commoner in the older
women. This may be due to the fact that women in
our locality are delaying childbearing to their thirties
perhaps as a result of increasing need to acquire
meaningful Western education. Increasing age is a
risk factor for fibroid growth.12 Several studies on
the incidence of myoma have been carried out in
different localities by different researchers around
the world and they observed that the incidences
obtained varied with the sample size and population
studied. In Poland for instance, Batoniak et al4
evaluated 670 women and obtained an incidence of
24%. They noted that myoma is commoner in
women of 25 years of age and above. The findings
of  those researchers suggest that women aged 25
years and over stand the risk of having myoma co-
existing with their pregnancy. These finding regarding
incidence and peak age for myoma development
differ from the findings of the present study and
may be due to racial variations. In Germany, Bosev
and Dimitrov13 found that solitary myomas were
dominant over multiple myomas. Their finding
corroborated the report of Exacoustos and Rosati14
in Italy. Contrary to this, however, in the present study,
multiple myomas were slightly more than single
myoma. Multiple myomas in pregnancy may pose
more serious complications such as preterm birth
and miscarriage.
Govan et al15 classified myomas into types
based on their location within the uterus and found
that intramural myomas account for about 70% of
all the types. Gross and Fleischer18 found 10% of
myomas in their study to be submucous and less
than 10% to be cervical, while Tsuda and Gross1
found the occurrence of subserous myomas to be
as high as 20% and retroplacental myomas to be
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less than 5%.  In this study subserous fibroid had the
highest incidence amongst other types/location
corroborating the findings of  Bosev and Dimitrov.13
Subserous myomas grow externally towards the
serosal covering of the uterus which causes the uterus
to be bumpy. As a result, most of  them are clinically
palpable and the smaller ones are usually
asymptomatic. However, large subserous myomas
may be symptomatic; they may press on surrounding
structures / organs causing pelvic pain. They seldom
affect menstrual flow or cause infertility. The location
of myoma in relation to the uterus and placenta has
a lot of  implications and may serve as a pointer to
obstetric management and mode of  delivery.
The present study reveals changes in size of
myoma during pregnancy. The rate of  growth rate
of myomas from first trimester to second trimester
was 0.667mm per week. This finding agrees with
that of Bosev and Dimitrov13 who studied the
changes in the myoma size during pregnancy in the
first, second and third trimesters. There was
significant correlation established between the myoma
size and GA in present study but no relationship
with maternal age. This implies greater risk of
complications as pregnancy advances. In the present
study, a reduction in myoma size was noted in the
3rd trimester (3rd scan sequence) and this appears
to be inconclusive due to the number of subjects
who later had abortion.  Several studies17-20 opined
that myoma cell hypertrophies during pregnancy and
later shrinks in late pregnancy and this probably
explains the observed fibroid growth trend in our
study. The cells in small fibroids enlarge during
pregnancy and shrink in late pregnancy. The decrease
in size observed in late pregnancy, by some studies,
could be explained in part by the decrease in cell
size. Myoma cells have a greater number of estrogen
receptors than surrounding normal myometrial cells.3
Therefore, these cells are more responsive to the
increased concentration of estrogen (estrogen surge)
during pregnancy and exceed the growth of the
surrounding myometrium. Progesterone on the other
hand may inhibit the growth of fibroids and even
induce degenerative changes and involution21-22. The
increasing progesterone level in late pregnancy could
explain the decrease in fibroid size during that period.
Another theory implicates decreased arterial supply
to fibroid as a cause of degeneration and decrease
in size.23 The implications of this growth pattern are
complications of pregnancy which may be based
on the number, location and size of the myoma.
In the present study, fibroids were associated
with obstetric complications such as bleeding,
abortion and intra uterine growth restriction (IUGR).
These findings corroborated the result obtained in
Germany by Aydeniz et al24. In this present study,
no placenta abruption was observed. Rice et al25
reported that pain and preterm birth correlated
positively with the size of  myoma. Vergani et al26
reported that caesarean section (CS) was more
common in women with myoma than the general
population of parturient. They opined that CS was
significantly higher in cases of myoma in the lower
uterine segment compared with myoma at the
fundus and, that CS was performed more when
mean diameter of myoma exceeds 5 cm. Batoniak
et al4 also reported similar findings that increased
incidence of  preterm birth were observed in patients
with uterine myoma larger than 600 cm³. Our study
shows that a significant number of pregnant women
with myoma had caesarean section (CS). Majority
of cases in which myoma size was between 61mm
and 100mm and >100mm resulted in CS. It can
therefore be deduced from this study that large
fibroids constitute greater risk of  CS than small ones.
The commonest obstetric complication in
patients with myoma in this study was abortion. This
could be attributed to the number, location/type
and size of  the myomas. Jabiry-zieniewicz and
Gajewska27 did a study on the outcome of
pregnancy with myoma and concluded that abortion
was the most eventful amongst other outcomes. The
second commonest complication in subjects with
myoma noted in this study was the syndrome of
painful myomas, sometimes associated with
bleeding, and probably related to haemorrhagic
degeneration or infarction. Although the aetiology
of the syndrome of painful myomas of pregnancy
is rather unclear, high concentrations of progesterone,
as in pregnancy, may play a role, as similar changes
of “red degeneration” have been induced by high-
dosage progestin therapy.22 Pain was also noted in
the group without myomas but in smaller number
of  subjects. Our study also showed that the
complications such as abortion, pelvic pains,
malpresentation and preterm delivery were seen to
be more prevalent in patients with myomas than
those without myomas. Caesarean section was
performed more in subjects with myomas than those
without myomas.
This study met with some difficulties while
being conducted. Difficulty was encountered during
measurement of very large fibroids in the third
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trimester. Measurement of  fibroids in the same plane
in subsequent scans was a challenge and the subjects
under study reduced in number from100 in the first
and second scan sequences to 85 in the third scan
sequence due to abortion. The findings in this study
should be considered with these imposed limitations
and difficulties taken into consideration.
Conclusion
Fibroids co-existing with pregnancy grow at the rate
of 0.667mm per week especially from first trimester
to second trimester. The occurrence of  myoma in
pregnancy was 12.3% and was found to be
commoner in older parturients. Myomas co-existing
with pregnancy contribute a high percentage of
obstetric complications and these complications are
more with increasing myoma size.
Recommendations
Routine ultrasound scan is recommended to all
pregnant women and should be performed carefully
between 18 to 22 weeks gestation.
Sonography of pregnant patients with co-existing
myomas should aim at:
Confirming presence of  myoma.
Location of myoma in the uterus and
relationship with the placenta.
Number and size of  the myomas.
Scanning of the entire abdomen/pelvis for any
associated lesions.
This would serve to identify pregnant women
at risk for myoma-related complications and
how best they can be managed.
Follow-up scans are recommended to determine any
change in size of  myoma as the pregnancy progresses.
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